The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual acuity and neovascularization area.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Ranibizumab (Lucentis), intravitreal injections of 0.05ml
Panretinal photocoagulation with green laser according to ETDRS
University of São Paulo
Ribeirão Preto, São Paulo, Brazil
Fluorescein leakage area (mm2)
Neovascularization area measured during fluorescein agiography middle phase
Time frame: Week 48 after inclusion in the study
CMT
Macular thickness measured with Stratus OCT protocols
Time frame: Week 48 after inclusion in the study
LogMAR BCVA
LogMAR best corrected visual acuity measured with ETDRS charts
Time frame: Week 48 after inclusion in the study
Retina mid periphery visual field sensitivity change
Time frame: Week 48 after inclusion in the study
Rod pathway integrity and oscillatory potential amplitudes
Time frame: Week 48 after inclusion in the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.